Additionally, the effectiveness of PARP inhibition in the radiosensitisation of HNSCC cells and tumours has been linked with SMAD4 involved in TGFβ signalling and where SMAD4-deficient models were shown to be more responsive to the combined treatment (30). The gene discussed is TGFB1; the disease is neoplasm.